# Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

> **NCT05431543** · PHASE2 · COMPLETED · sponsor: **LENZ Therapeutics, Inc** · enrollment: 59 (actual)

## Conditions studied

- Presbyopia
- Refractive Errors
- Eye Diseases

## Interventions

- **DRUG:** Aceclidine+Brimonidine combination ophthalmic solution
- **DRUG:** Aceclidine ophthalmic solution
- **DRUG:** Vehicle proprietary ophthalmic solution

## Key facts

- **NCT ID:** NCT05431543
- **Lead sponsor:** LENZ Therapeutics, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-06
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431543, "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05431543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*